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Current risk stratiﬁcation for thrombosis in essential thrombo-
cythemia (ET) is two-tiered and considers low- and high-risk
categories based on the respective absence or presence of either
age 460 years or history of thrombosis.1 In the recent
International Prognostic Score for Thrombosis in ET (IPSET-
thrombosis), age and history of thrombosis were conﬁrmed as
independent risk factors for future thrombosis and the study also
identiﬁed independent prothrombotic role for cardiovascular (CV)
risk factors and JAK2V617F mutation.2 This model outperformed
the two-tiered conventional risk stratiﬁcation in predicting future
vascular events and was not further affected by the recently
discovered CALR mutation.3 In the current study, we re-analyzed
the original IPSET-thrombosis data in 1019 patients with WHO-
deﬁned ET in whom JAK2 mutational status was available, to
quantify the individual contributions of JAK2 mutations and CV
risk factors in conventionally assigned low- and high-risk ET.
After approval from their respective institutional review boards,
seven centers from Italy, Austria and the United States, belonging
to the International Working Group for myeloproliferative
neoplasm (MPN) Research and Treatment (IWG-MRT), collectively
submitted diagnostic and follow-up information on 1220 patients,
locally diagnosed with ‘WHO-deﬁned ET’.4 Among these, 1019
patients were selected in whom JAK2 mutational status was
available. Objectively proven major arterial and venous events2
were reported as rates per 100 patient-years and the difference
among groups was assessed by Mantel Cox log-rank test. The
Kaplan–Meier product-limit method was used to estimate
thrombosis-free survival curves, and the log-rank test was adopted
to compare survival curves.
At diagnosis, conventionally assigned low-risk and high-risk
groups were signiﬁcantly different in terms of the frequency of CV
risk factors (Po0.001) and JAK2 mutational status (Po0.001).
Median follow-up was 6.8 and 5.0 years in conventionally
assigned low- and high-risk patients, respectively. Low-dose
aspirin and cytoreduction drugs (Hydroxyurea in around 85%)
were prescribed in 58 and 41% in low-risk and in 71 and 81% in
high risk, respectively. In low-risk patients cytoreduction was
started after a median of 18 months since diagnosis because of
occurrence of vascular events, age rising to 60 years or progressive
thrombocytosis. The overall annual rate of total thrombosis
(108 events) in conventionally assigned low- and high-risk patients
was 1.11%-pt/y (conﬁdence interval (CI) 0.81–1.52) and 2.46%-pt/y
(CI 1.94–3.11), respectively (P= 0.001), and the difference was
mainly due to a higher frequency of arterial thrombosis in high-
risk patients (Po0.001).
The inﬂuence of JAK2 mutations and CV risk factors on the rate
of thrombosis in conventionally assigned low- and high-risk
groups is presented in the table.
(i) Conventionally assigned low-risk group. Amongst 506
patients, 200 (40%) displayed neither JAK2 mutation nor CV risk
factors and their annual rate of thrombosis was 0.44%, as opposed
to 1.05% in the presence of CV risk factors (P=not signiﬁcant (NS)),
1.59% in the presence of JAK2 mutation (P= 0.001) and 2.57% in
the presence of both CV risk factors and JAK2mutation (Po0.001).
There was no signiﬁcant difference when low-risk patients with
both JAK2 mutation and CV risk factors were compared with those
with JAK2 mutation only (P= 0.217). Figure 1 a shows the time to
major thrombosis among patients with the absence or presence of
one or two additional risk factors (that is, JAK2 mutations and CV
risk factors).
(ii) Conventionally assigned high-risk group: the absence or
presence of one or both of the aforementioned additional risk
factors for thrombosis were documented in 111 (22%), 44 (9%),
222 (43%) and 136 (27%) patients, respectively, with correspond-
ing annual rates of thrombosis at 1.44, 1.64, 2.36 and 4.17%
(Table). High-risk patients with both risk factors had a signiﬁcantly
higher risk of thrombosis compared with their counterparts
without JAK2 mutations and CV risk factors (P= 0.011). Figure 1
b shows the probability of events in the groups.
Additional analysis revealed limited enhancement of thrombo-
sis risk by either JAK2 mutations or CV risk factors or both in
patients whose high-risk status was deﬁned by the presence of
thrombosis history, regardless of age (P=NS). In contrast, the
presence of JAK2 mutations, with or without CV risk factors, might
have affected thrombosis risk in patients where high-risk status
was deﬁned by age alone (P= 0.05).
The current study quantiﬁes the individual and combined
risk contribution of CV risk factors and JAK2 mutation in
both conventionally deﬁned low- and high-risk ET. The
impressively low risk of thrombosis in low-risk JAK2-unmutated
patients with (1.05% patients/year) or without (0.44%
patients/year) CV risk factors clearly distinguishes them
from conventionally assigned ‘low-risk’ patients with JAK2
mutations, with or without CV risk factors. It is therefore
reasonable to further risk-stratify conventionally assigned
‘low-risk’ ET into ’very low risk’ and ‘low risk’ categories, based
on the respective absence or presence of JAK2 mutations
(Figure 1c), with the caveat that ’very low risk’ disease without
CV risk factors is therapeutically approached differently than
‘very low risk ‘ disease with CV risk factors. Such distinction is
practically relevant because aspirin therapy might not be
necessary in the former group, whereas its efﬁcacy in the latter
group and in those with ‘low risk’ disease as suggested in a
recent retrospective study5 might have been undermined by the
lack of 24 h therapeutic coverage from the standard once-daily
aspirin, especially in JAK2-mutated patients with or without CV
risk factors.6,7
In high-risk ET, among the two conventional risk factors, the
current study delineates thrombosis history as being signiﬁcantly
more detrimental than advanced age. Furthermore, the effect of
JAK2 mutations and CV risk factors in high-risk disease was more
apparent, although not statistically signiﬁcant, in patients whose
high-risk disease status was determined by advanced age,
whereas the additional impact of these additional risk factors
was not signiﬁcant in high-risk patients with history of thrombosis.
This suggests the possible consideration of older patients without
thrombosis history or JAK2 mutations as ‘intermediate-risk’ and
reserve the ’high-risk’ label to patients with thrombosis or to
those who are 460 years but also display JAK2 mutations. In
other words, the revised risk stratiﬁcation scheme might include
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four categories: ‘very low risk’ (no thrombosis history, age
⩽60 years and JAK2-unmutated); ‘low risk’ (no thrombosis history,
age ⩽60 years and JAK2-mutated); intermediate risk’
(no thrombosis history, age 460 years and JAK2-unmutated) and
high risk (thrombosis history or age460 years with JAK2 mutation).
Figures 1 c and d show the thrombosis-free survival probability of
patients according to this revised risk stratiﬁcation.
Treatment recommendations for each one of the above-
mentioned new risk categories should be examined in the context
of prospective controlled studies. Until results from controlled
studies become available, we would not insist on the use of aspirin
in ‘very low risk’ disease without CV risk factors while we advise
once-daily aspirin in ‘very low risk’ disease with CV risk factors.
We believe that it is reasonable, but not mandated, to consider
twice-daily aspirin in ‘low-risk’ JAK2-mutated patients, especially in
the presence of CV risk factors. Similarly, although we encourage
the use of cytoreductive therapy in both ‘intermediate risk’ and
‘high risk’ disease, we would not insist in its use in ‘intermediate-
risk’ patients, who could be treated, instead, with twice-daily
aspirin.
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Figure 1. Thrombosis-free survival in conventionally deﬁned low- and high-risk (a and b) and in the revised risk classiﬁcation (c and d).
(a) Low-risk patients with or without additional risk factors (CV risk factors and JAK2 mutation); (b) High-risk patients with or without
additional risk factors (CV risk factors and JAK2 mutation); (c) ‘Very low risk’ (no thrombosis history, age ⩽ 60 years and JAK2-unmutated);
‘Low risk’ (no thrombosis history, age ⩽ 60 years and JAK2-mutated); (d) ‘Intermediate risk’ (no thrombosis history, age460 years and JAK2-
unmutated); ‘High risk’ (thrombosis history or age 460 years with JAK2 mutation).
Table 1. Inﬂuence of cardiovascular risk factors and JAK2 mutation on the rate of vascular events in low- and high-risk patients
Additional risk factors N (%) Event Rate% patients/year (95% CI) P-value P-value P-value trend
Low risk 506 (50)
None 200 (40) 7 0.44 (0.21–0.92) Ref
Cardiovascular risk factor 36 (7) 3 1.05 (0.34–3.25) 0.220 0.227
JAK2V617F 213 (43) 21 1.59 (1.04–2.44) 0.001 0.217
Both 52 (10) 8 2.57 (1.29–5.15) o0.001 Ref o0.001
High risk 513 (50)
None 111 (22) 10 1.44 (0.78–2.68) Ref
Cardiovascular risk factor 44 (9) 4 1.64 (0.62–4.37) 0.909 0.067
JAK2V617F 222 (43) 30 2.36 (1.65–3.38) 0.168 0.082
Both 136 (27) 25 4.17 (2.82–6.17) 0.011 Ref 0.005
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